Rethinking CIRS: Innate Immune Dysregulation as the Upstream Driver Beyond Inflammation and Genetic Susceptibility

Author: Alli Manzella, CIRS-Literate FNTP, Environmental Health Specialist
Co-Founder, Root Cause for Crohn’s & Colitis (RCFCC)
Date: June 2025

​

Introduction

​

Chronic Inflammatory Response Syndrome (CIRS) is widely recognized as a multisystem illness triggered by biotoxin exposure in genetically susceptible individuals, particularly those carrying specific HLA-DR/DQ haplotypes. Current clinical paradigms emphasize persistent innate immune activation and inflammation as defining features of this condition. However, this framework may be incomplete.

​

While inflammation is a prominent clinical feature, it does not fully explain the persistence, variability, and multisystem nature of disease observed in many patients. In particular, it remains unclear why certain individuals fail to resolve immune activation following exposure, while others recover.

 

Emerging research and clinical observations suggest that impaired regulation of innate immune function may underlie this failure of resolution. This dysfunction appears particularly evident in individuals carrying HLA-DR4-3-53 and DR11-3-52B haplotypes, which are associated with altered antigen presentation and impaired immune recovery following exposure.

​

In this context, the host loses the capacity to appropriately regulate recognition, clearance, and recovery processes, resulting in a state of persistent innate immune dysregulation. Within this framework, inflammation, immune exhaustion, and ongoing sensitivity to environmental and endogenous triggers emerge as downstream consequences rather than primary drivers of disease.

​

Foundational Roles of Innate Immune Function

​

To understand how innate immune dysregulation drives disease in this model, it is first necessary to define the normal roles of innate immune function. The innate immune system is not limited to pathogen defense, but serves as a central regulatory network governing immune surveillance, barrier integrity, and resolution of inflammation. Disruption of these functions provides a mechanistic basis for the persistent, multisystem features observed in CIRS.

​

The innate immune system functions as the body’s first line of defense and a central regulator of immune homeostasis. Its roles include:

​

• Regulation of adaptive immune responses

• Pattern recognition through receptors such as TLRs, NLRs, and CLRs

• Maintenance of physical and immune barriers, including the gut, lung, skin, brain, and mucosal surfaces

• Pathogen clearance and apoptotic cell removal

• Regulation of immune tolerance and resolution of inflammation

• Metabolic and endocrine homeostasis

• Surveillance against malignancy and abnormal self-patterns

​

When dysregulated, this system no longer maintains homeostasis and begins to fail in its core functions:

​

• Inadequate clearance of biotoxins and cellular debris

• Breakdown of immune tolerance

• Persistent activation of inflammatory signaling pathways

• Impaired antigen presentation and communication with adaptive immunity

​

Key clinical indicators of this dysfunction include:

​

• Low α-MSH and VIP, reflecting disruption of neuroimmune signaling

• Reduced NK cell activity, impairing innate pathogen clearance

• Thymic involution, indicating reduced naïve T cell production

• Elevated TGF-β1, associated with compensatory immune suppression and fibrosis

​

These findings are not merely consequences of inflammation, but reflect a failure of innate immune regulation in genetically susceptible individuals, particularly those carrying HLA-DR4-3-53 and DR11-3-52B haplotypes.

​

Rethinking HLA Genetics: Marker or Mechanism?

​

Approximately 24 percent of the population carries HLA haplotypes associated with increased susceptibility to CIRS. However, the presence of these haplotypes alone is insufficient to explain disease onset or persistence.

​

HLA genetics influence immune responses through antigen presentation dynamics, shaping how the immune system recognizes and responds to environmental inputs. Most individuals carrying “CIRS-susceptible” haplotypes remain asymptomatic unless exposed to a sufficient environmental or physiological stressor. This suggests that while HLA contributes to susceptibility, it does not fully explain why the immune system fails to resolve activation following exposure.

​

In particular, HLA-DR4-3-53 and HLA-DR11-3-52B haplotypes have been associated with altered antigen presentation, immune misrecognition, and impaired immune resolution. These patterns appear to be linked with a higher propensity toward innate immune dysregulation, rather than functioning as independent causal mechanisms.

​

Shoemaker and Heyman (2020) describe these genotypes as contributing to an altered host response, particularly in the context of biotoxin exposure and transcriptomic immune suppression. Suppression of the CD3D gene, which is required for T cell signaling and B cell activation, has been identified as a key feature. This contributes to impaired immune coordination and helps explain why some patients exhibit features of immune exhaustion rather than overt hyperinflammation.

​

As described by Dr. Heyman, this state reflects not classical immunosuppression, but a form of transcriptomic injury in which immune resolution pathways are impaired. This distinction is critical, as it highlights a failure of immune regulation rather than simple immune deficiency.

​

Taken together, these findings suggest that HLA haplotypes act as modifiers of immune response rather than primary drivers of disease. The persistence of illness is more accurately explained by failure of innate immune regulation, including disruption of pattern recognition, mitochondrial signaling, and immune checkpoint function.

​

Biotoxins as Initiators of Innate Immune Injury

​

Environmental biotoxins, including mycotoxins, bacterial endotoxins, and marine toxins, initiate immune responses through pattern recognition receptors (PRRs) such as Toll-like receptors and C-type lectin receptors. These signaling pathways are designed to detect conserved molecular patterns and mount a rapid innate immune response. However, for these interactions to occur systemically, biotoxins must first interact with or bypass physical and immune barriers.

​

In a healthy host, barrier systems remain intact and exposures trigger a controlled, self-limited immune response. Activation is followed by effective clearance and resolution, allowing restoration of homeostasis.

​

In contrast, when innate immune regulation is impaired, barrier integrity and immune coordination are compromised. Disruption of epithelial and mucosal barriers facilitates increased interaction between biotoxins and immune cells, while impaired clearance mechanisms prevent completion of the immune response. This results in persistent activation of inflammatory signaling pathways, insufficient resolution, and ongoing immune dysregulation.

 

Within this context, biotoxins act as initiating factors rather than sustaining drivers of disease. Once innate immune dysregulation is established, endogenous factors including microbial metabolites, translocated lipopolysaccharides, and latent or persistent pathogens may serve as secondary drivers of immune activation. These internal sources of biotoxic burden perpetuate inflammatory signaling in the absence of ongoing external exposure.

 

This transition from exogenous trigger to endogenous amplification helps explain the persistence and progression of disease observed in CIRS. The central pathological mechanism is therefore not the continued presence of biotoxins alone, but the failure of innate immune resolution and restoration of immune homeostasis.

​

Immune Exhaustion, Metabolic Injury, and Tolerance Shifts

​

Clinical and laboratory findings in CIRS often reflect features of immune exhaustion rather than classical hyperinflammation. These patterns point toward a failure of immune regulation and resolution, rather than persistent overactivation alone.

​

Common findings include:

​

• Low MSH and VIP, reflecting impaired neuroimmune regulation of epithelial and immune function

• Elevated TGF-β1 and MMP-9, reflecting impaired immune resolution, tissue remodeling, and sustained inflammatory signaling

• T cell exhaustion and thymic involution, indicating impaired renewal of adaptive immune surveillance

​

Transcriptomic analysis further reveals suppression of CD3D, a gene essential for antigen-presenting cell to T cell signaling. Impairment of this pathway disrupts coordination between innate and adaptive immunity, leading to reduced B cell activation, loss of regulatory function, and ineffective immune resolution. This helps explain the coexistence of persistent inflammation with features of immune deficiency observed in both CIRS and IBD.

 

Metabolic dysfunction is a central component of this process. Shoemaker and Heyman describe a state of hypometabolism in CIRS, characterized by suppression of mitochondrial translocase activity, which prevents pyruvate from entering the mitochondria. As a result, cellular energy production shifts from oxidative phosphorylation to glycolysis. This Warburg-like metabolic pattern yields significantly reduced ATP production, contributing to impaired function in immune and epithelial cells.

​

Similar patterns have been observed in chronic infections, cancer, and post-sepsis states, where unresolved immune activation leads to metabolic reprogramming, loss of immune vigilance, and systemic energy failure. The parallels across these conditions support a shared mechanism in which persistent immune activation, in the absence of effective resolution, drives both immune exhaustion and metabolic collapse.

 

Within this framework, immune exhaustion and metabolic dysfunction are not solely consequences of genetic susceptibility, but reflect downstream effects of impaired innate immune regulation. Failure to resolve innate immune activation leads to progressive loss of immune coordination, reduced surveillance, and sustained dysfunction across multiple systems.

​

Implications for Clinical Practice

​​

The CIRS Treatment Protocol provides a structured and clinically validated framework for addressing biotoxin-related illness. Its stepwise approach, including removal from exposure, bile acid sequestration to support elimination of circulating biotoxins, correction of inflammatory biomarkers, and restoration of neuroimmune signaling, plays a critical role in reducing total biotoxin burden and stabilizing the patient.

​

These interventions are essential for mitigating ongoing exposure, lowering inflammatory signaling, and creating the physiologic conditions necessary for recovery. However, while the protocol effectively addresses biotoxin burden and downstream inflammatory pathways, it does not directly restore the underlying regulatory function of the innate immune system in all patients.

​

Reframing CIRS as a disorder of innate immune dysregulation expands this model. In this context, impaired immune regulation represents the central pathology, and downstream features such as inflammation, chronic infection, microbial imbalance, and barrier dysfunction are secondary consequences rather than primary targets of treatment.

​

Within this framework, clinical strategy can be understood as both reduction of biotoxin burden and restoration of innate immune function. While the CIRS Treatment Protocol addresses the former, restoration of immune regulation remains a critical therapeutic objective for achieving durable resolution.

 

Innate immune retraining strategies, including site-specific immunomodulation, represent a fundamentally different approach aimed at correcting the underlying dysfunction rather than suppressing its downstream effects. QuBiologics’ Site-Specific Immunomodulation (SSI), exemplified by QBECO, utilizes sterile, heat-killed Escherichia coli administered subcutaneously to induce localized chemokine signaling and targeted recruitment of innate immune cells. This process promotes reprogramming of innate immune transcriptional responses, with reported effects including restoration of natural killer cell activity, enhanced antigen presentation, and improved immune surveillance. Notably, QBECO is formulated without endotoxins, antigenic proteins, or adjuvants and is delivered in preservative-free saline, contributing to a favorable safety and tolerability profile.

​

Through these mechanisms, innate immune retraining facilitates improved coordination between innate and adaptive immunity and enhances the host’s capacity to regulate microbial populations, clear persistent immune stimuli, and restore barrier integrity. Importantly, this approach is not dependent on the specific initiating trigger, but instead addresses the shared downstream consequence of immune dysregulation.

​

Early clinical investigations in moderate to severe chronic inflammatory conditions, including Crohn’s disease and ulcerative colitis, have reported medication-free remission rates of approximately 65 to 76 percent following QBECO therapy. While these findings require further validation in larger controlled trials, they contrast with the more limited remission rates observed with conventional pharmacologic approaches.

​

These findings may reflect a broader mechanism of action extending beyond gastrointestinal disease. QBECO has also shown activity in other conditions associated with innate immune dysfunction. In oncology settings, restoration of natural killer cell cytotoxicity and improved tumor antigen recognition have been linked to enhanced immune-mediated clearance of malignant cells in early-stage investigations.

​

Given the complementary mechanisms of action, combining the CIRS Treatment Protocol with innate immune retraining may offer a synergistic approach by addressing both environmental burden and the underlying failure of immune regulation.

​

This model suggests that effective treatment of CIRS depends not only on reducing biotoxin exposure, but on restoring the host’s intrinsic capacity for immune regulation and recovery.

 

Figure 1. Mechanism of Innate Immune Retraining and Systemic Immune Restoration​​​​​​​​​​​​​​​​​​